whirlinGenealiases: CIP98 · DFNB31 · PDZD7B · USH2D · WI
Q-omics provides the consensus-scored WHRN profile across patient tissues and cancer cell-line models. WHRN expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WHRN is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, WHRN protein abundance shows 23,150 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where WHRN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WHRN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WHRN survival associations across molecular data types. WHRN RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WHRN RNA expression–survival associations across cancer types. High WHRN expression shows unfavorable associations in KIRC, LGG, LIHC, LUSC and PRAD, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for WHRN RNA expression.
This table summarizes WHRN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WHRN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WHRN shows lower tumor expression in THCA and BLCA and higher tumor expression in COAD, LIHC, KIRP and HNSC. The COAD box plot shows higher WHRN RNA expression in tumor versus normal tissue (log2 FC = +1.094, t-test p < 0.001).
This table shows molecular features associated with WHRN in patient tissues and cancer cell lines. In patient samples, WHRN shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, WHRN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
